ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000.

This should not be seen as good news for any given technology (iFR, in this case), but for physiologic assessment as a general concept. Many more interventional cardiologists need to start using physiologic assessment as a standard course of action in their cath labs, because there is much evidence that it improves outcomes.

 

FFR requires maximum hyperemia, which is achieved by using adenosine—with its associated side effects and costs. On the other hand, iFR calculates the pressure gradient of a lesion during diastole, immediately after the dicrotic wave, when physiologic resistance is minimum. That renders unnecessary the use of hyperemic agents.


Read also: NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising.


Last year, DEFINE-FLAIR and iFR-SWEDEHEART results proved the noninferiority of iFR in terms of events compared with FFR measurement.

 

The difference in terms of costs is driven by the fact that FFR-guided procedures identified more significant lesions that required treatment. More time must go by for the assessment of this aspect. If, in the future, some lesions left untreated with iFR require reintervention, the equation might be inverted by the late catch-up phenomenon. The opposite might also turn out to be true: less stenting with iFR might derive in less restenosis and less future thrombosis.

 

Original title: Comparative Cost-Effectiveness of the Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Coronary Revascularization Decision-Making.

Presenter: Patel MR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...